Our study provides initial insights into IGFBP6 and sepsis, but there are still some limitations: (a) Although IGFBP6 knockout models show therapeutic potential, the clinical translatability of genetic ablation is limited, and specific neutralizing antibodies or inhibitors targeting IGFBP6 remain undeveloped. The gene discussed is IGFBP6; the disease is Sepsis.